financetom
Business
financetom
/
Business
/
Pig iron business aided by pent-up demand & shortage of supply: Tata Metaliks
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pig iron business aided by pent-up demand & shortage of supply: Tata Metaliks
Jan 20, 2021 2:03 AM

Tata Metaliks' ductile iron (DI) pipes division disappoints a bit due to shutdown for a couple of weeks during the third quarter, but the pig iron segment did very well for them.

On pig iron performance, Sandeep Kumar, Managing Director at Tata Metaliks said, “The pig iron has been a star and this is led by two factors—one is the pent-up demand and the other is the shortage of supplies. The third reason is the way the raw material prices are moving up but there is always a lag and it also depends on who has control over coke.”

Pig iron spreads at Rs 12,000 per tonne but Kumar expects it to taper down in Q4FY21.

“Spreads are fantastic, upwards of Rs 12,000 per tonne which is typically on an average about Rs 5,000. As we go into Q4, expect these spreads to come down somewhat, but it would vary from producer to producer depending on who has control over raw materials.”

On volumes, Kumar said, “Pig iron market was doing well and DI was bit slow in terms of project funding coming in from the government. We would typically do it at the same levels, may be somewhat higher because the blast furnace would be in full flow this quarter so the volumes of DI pipe would certainly go up, on pig iron may be marginally up.”

On the waste heat recovery plant, the Tata Metaliks' Kumar said, “We are commissioning the new unit by next month and I think full production should start from March. That will also give us some more advantage as we go forward. More importantly, we will also have the fourth power plant coming in which is a 15-megawatt power plant which is to time with the new expansion of the DI pipe unit and that is going to take some time.”

Watch the video for more

(Edited by : Ajay Vaishnav)

First Published:Jan 20, 2021 11:03 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hims & Hers Health Insider Sold Shares Worth $1,051,087, According to a Recent SEC Filing
Hims & Hers Health Insider Sold Shares Worth $1,051,087, According to a Recent SEC Filing
Jun 21, 2024
04:39 PM EDT, 06/21/2024 (MT Newswires) -- Andrew Dudum, 10% Owner, Director, Chief Executive Officer, on June 20, 2024, sold 45,755 shares in Hims & Hers Health ( HIMS ) for $1,051,087. Following the Form 4 filing with the SEC, Dudum has control over a total of 11,130,533 shares of the company, with 33,502 shares held directly and 11,097,031 controlled...
Thunder Power Completes Merger with Feutune Light Acquisition
Thunder Power Completes Merger with Feutune Light Acquisition
Jun 21, 2024
04:48 PM EDT, 06/21/2024 (MT Newswires) -- Thunder Power Holdings said Friday it has completed the business combination with blank check firm Feutune Light Acquisition ( FLFV ) . The shares of the combined business, Thunder Power Holdings, are expected to begin trading Monday on the Nasdaq Global Market under the ticker AIEV. Price: 2.5100, Change: -0.05, Percent Change: -1.95...
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
Jun 21, 2024
04:43 PM EDT, 06/21/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Friday it received approval from the European Commission for Fruzaqla for the treatment of previously treated metastatic colorectal cancer. The company secured the US Food and Drug Administration's approval of Fruzaqla as colorectal cancer treatment in November. ...
BRIEF-Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
BRIEF-Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Jun 21, 2024
June 21 (Reuters) - Eiger Biopharmaceuticals Inc ( EIGRQ ): * COMPANY AND AMYLYX ENTERED INTO AN ASSET PURCHASE AGREEMENT * AMYLYX AGREED TO BUY ALL OF CO'S RIGHTS, TITLE,INTERESTS IN ASSETS,INTERESTS USED IN DEVELOPMENT, MANUFACTURE,COMMERCIALIZATION OF AVEXITIDE * ASSET PURCHASE AGREEMENT FOR $35.1 MILLION, PLUS AGGREGATE AMOUNT OF DETERMINED CURE COSTS AND ASSUMED LIABILITIES ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved